Member Info for Bobat123

Last year June was 20p. How times have changed. Hopefully this Rns will try and get it back up now

RNS printed on the LSE Board. Excellent news. Should see peeps loading onto this share now.

Ey CYP2C19-ID test performance milestone achieved

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to announce that a key milestone has been met in The Development and Validation of Technology for Time Critical Genomic Testing ("DEVOTE") programme for its CYP2C19-ID kit. The programme has now passed the patient numbers required for a subsequent submission for an in vitro diagnostics CE certification ("CE-IVD"), which is still anticipated in early 2025.

The Genedrive® CYP2C19-ID point of care genetic test is UK Conformity Assessed ("UKCA") certified, uses a single, non-invasive cheek swab sample, and rapidly identifies several important genetic variants of the CYP2C19 gene (Loss Of Function ("LoF")), which are instrumental in an individual's response to the drug clopidogrel which can be prescribed in Ischemic Stroke ("IS") and Transient Ischaemic Attack ("TIA"). The test automatically interprets the CYP2C19 DNA variant information for the clinician and allows for prompt administration of an alternative treatment plan for the circa 30% of individuals that are less likely to respond favourably to clopidogrel.

DEVOTE is an all-comer study in which CYP2C19 DNA variants in patients presenting in the acute emergency care setting are tested with the Genedrive® CYP2C19-ID test and results compared with those obtained by reference laboratory platform testing, with testing on a third laboratory platform in instances where there is disagreement in test results. In the tests run to date the Genedrive® CYP2C19-ID test has out-performed the reference laboratory-based test with respect to coverage of LoF variants and accuracy (correct identification of variant).

The DEVOTE programme, through its lead partner the University of Manchester ("UoM"), has supported the Company's requirement for assessing performance in acute care patients and provided valuable supporting infrastructure to assess the real-world clinical performance of time-critical clinical tests in NHS settings. The study addresses clinical requirements of the In Vitro Diagnostic Medical Devices Regulation ("IVDR") for CE-IVD submission and subsequent commercialisation in those countries recognising CE-IVD, in addition to current UKCA certification allowing UK commercialisation.

Approximately 30% of patients in the cohort harboured CYP2C19 LoF variants as expected. The Genedrive® CYP2C19 test outperformed the laboratory test with respect to accuracy of identification of LoF alleles, and broader inclusion of LoF alleles. Genedrive® CYP2C19-ID test results are available in ~70 minutes.

The UK's National Institute for Health and Care Excellence ("NICE") has recommended in draft guidance, that the Genedrive® CYP2C19-ID test should be used as the point-of-care test of choice in the NHS before clopidogrel administration in the management of IS and TIA patients (https://www.nice.org.uk/guidance/indevelopment/gid-d

Many peeps from VAL profits piling in now. Canada market also opening back today. Will be interesting to see how the day develops.

6.6p to sell. MMs want shares.

BUys coming in.

This is being held back. MMs printing buy from the morning now.

Same Again. Not giving quote to buy any large amounts

Further re Final Results

ValiRx plc (the "Company") (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, announces that, following the publication of its audited results for the year ended 31 December 2023 on 15 May 2024 and shareholder feedback and communication, a clarification as to its cash position and recent fundraising activities.

As stated in the announcement of 15 May 2024, the cash balance of the Company as at 31 December 2023 was £174,684.

Get rid of stop losses. Mms keep trying to hit them to gain shares

Ken Armstrong, Interim CEO of Cornish Metals, commented: "The Company is unaware of any reason for the selling pressure on the Cornish Metals share price this week. We believe the PEA reported on April 30, 2024 is robust and represents a strong foundation for further evaluation of the South Crofty tin project. South Crofty is fully permitted for mining through to 2071 and has planning permission in place to construct a process plant and other surface facilities on Company owned land adjacent to New Cook's Kitchen shaft. South Crofty is a strategic high-grade tin asset that is well positioned to take advantage of the strong demand for tin, which we believe due to its critical nature and continued supply uncertainty, is likely to continue to trade above the PEA tin price assumption of US$31,000 per tonne."

Mms not giving quote to buy any large amounts

Hopefully see this moving up now

Will we get another RNs from the BOD on Monday? We will have to wait and see.

BOD will have to release another RNs .

Criminal from mms. Going for stop losses and took this down

Cannot believe peeps taking their 10% . Good luck to them.

Alliance News Now:

On London's AIM, Cornish Metals shares partially rebounded 24% to 7p on Friday morning. The stock plummeted by 42% from 9.98 pence on Monday to 5.68p on Thursday.

The Vancouver-based mineral exploration company reassured investors and said that "it is unaware of any operational or corporate reason for the price movement".

Buys from earlier Mms printing them as sells

(Alliance News) - Cornish Metals Inc shares rose on Friday, after falling over the past week, as the company reassured its shareholders.

The Vancouver-based mineral exploration company early Friday noted the sharp fall in its share price this week.

The stock plummeted by 42% from 9.98 pence on Monday to 5.68p on Thursday. On Friday morning in London, however, the price rebounded by 20% back to 6.89p each.

Cornish Metals reassured investors and said that "it is unaware of any operational or corporate reason for the price movement".

Interim Chief Executive Ken Armstrong commented: "The company is unaware of any reason for the selling pressure on the Cornish Metals share price this week."

At the start of this month, Cornish Metals Inc said a recent economic assessment of its flagship South Crofty tin project had produced a promising financial profile, reaffirming the company's confidence in its flagship asset.

Cornish Metals said that a preliminary economic assessment reported a post-tax net present value of USD201 million for its 100% owned South Crofty tin project in Cornwall, England.

Armstrong said on Friday: "We believe the PEA...is robust and represents a strong foundation for further evaluation of the South Crofty tin project. South Crofty is fully permitted for mining through to 2071 and has planning permission in place to construct a process plant and other surface facilities on."

By Sophie Rose, Alliance News senior reporter